Boston Scientific (BSX) is back in focus after a worldwide Class I recall of its Imager II Angiographic Catheters, a safety event that raises fresh questions around risk, regulation and future capital deployment.
The recall has landed just as Boston Scientific’s share price has been under clear pressure, with the stock down 53.39% year to date on a share price basis and the 1 year total shareholder return falling 54.86%. However, the latest 1 day and 7 day share price returns of 2.65% and 5.00% suggest a short burst of positive momentum as investors weigh the catheter issue alongside upcoming earnings and the 2027 reorganisation into Interventional Therapies, Rhythm Solutions and MedSurg under a new COO structure.
Seize this moment around Boston Scientific's recall and restructuring story to reassess your exposure to quality healthcare names using our curated list of 32 resilient stocks with low risk scores.After a 53% slide this year and a short bounce on recall headlines and the 2027 reorganisation, is most of Boston Scientific’s rerating already in the rearview mirror, or does the valuation still point to meaningful upside ahead?
Most Popular Narrative: 26% Undervalued
Boston Scientific’s most followed narrative pegs fair value at about $59.72, compared with the last close at $44.14. This frames the current recall noise against a longer term earnings and capital return story.
Enhanced scale and operational efficiency are now anchored by a comprehensive restructuring program targeting about US$500m of annual run rate savings exiting 2029, combined with a US$2b share repurchase completed in Q2 2026. Together these actions are directed at supporting operating margin resilience and EPS growth even as near term guidance reflects WATCHMAN, EP and cyberattack related pressure.
See why 84 investors see Boston Scientific as 26% undervalued.
Result: Fair Value of $59.72 (UNDERVALUED)
Still, the recall streak and the execution risk around the US$14.5b Penumbra deal, along with US$700m to US$800m in restructuring charges, could derail the Boston Scientific upside case.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
Sentiment on Boston Scientific is clearly split, with real concerns on one side and clear upside arguments on the other. Move quickly, review the underlying numbers yourself and weigh both the 4 key rewards and 1 important warning sign.
Looking for more Boston Scientific investment ideas?
Do not stop at Boston Scientific. Use this moment to refresh your watchlist with fresh opportunities that fit your goals and risk tolerance through the Simply Wall Street Screener.
- Target resilient balance sheets and steady fundamentals by scanning our curated list of solid balance sheet and fundamentals (25 results) that can complement or contrast your Boston Scientific position.
- Hunt for potential mispricings by reviewing the 33 high quality undervalued stocks and see which stories the market may not be fully pricing in yet.
- Lock in a clearer income angle by filtering through the 8 dividend fortresses before the next round of payouts is already spoken for.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com